KCPG
SAGE

Kavar Capital Partners Group’s Sage Therapeutics SAGE Stock Holding History

Kavar Capital Partners Group’s Portfolio SAGE Stock Details SAGE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q1 		– Sell
-5
Closed – – 330
2015
Q4 		$0 Hold
5
– – ﹤0.01% 518
2015
Q3 		$0 Buy
+5
New +$308 ﹤0.01% 527

Other funds holding SAGE

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
VAM
Visium Asset Management New York $1.43B AUM 3.58% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
EAM
Eagle Asset Management St Petersburg, Florida $19.6B AUM 41.58% 1-Year Est. Return

Kavar Capital Partners Group's SAGE Position: Q1 2016 in Review

Kavar Capital Partners Group sold out of Sage Therapeutics (SAGE) in Q1 2016, closing a stake of 5 shares.

Kavar Capital Partners Group first reported a position in SAGE in Q3 2015 and held it in 2 quarters. The position peaked at $0 in Q4 2015. 144 funds tracked by Wall St. Rank hold SAGE as of Q1 2016.

  • Kavar Capital Partners Group reported no remaining Sage Therapeutics position as of Q1 2016 after selling out during the quarter.
  • Kavar Capital Partners Group sold 5 Sage Therapeutics shares in Q1 2016.
  • Kavar Capital Partners Group first reported a position in Sage Therapeutics in Q3 2015 and held it in 2 quarters.
  • Kavar Capital Partners Group's Sage Therapeutics position peaked at $0 in Q4 2015.
  • 144 funds tracked by Wall St. Rank held Sage Therapeutics as of Q1 2016.

Based on Kavar Capital Partners Group's 13F filing for Q1 2016, filed 13 May 2019.